ACCESS Newswire
26 Jan 2022, 18:20 GMT+10
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event at the 2022 OBIO Investment Summit hosted by the Ontario Bioscience Innovation Organization.
As part of an industry panel, Dr. Nijhawan is expected to discuss, among other topics, how Edesa adapted its drug development programs and aligned its business with government and industry priorities to respond to the COVID-19 health crisis.
The panel discussion, which is titled 'Pivoting and Adapting to the Changing Environment,' is scheduled to take place on Thursday, February 10, 2022 at 1:00 pm Eastern Time. More information is available at the event website.
About Edesa Biotech, Inc.
Edesa Biotech, Inc. (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory and immune-related diseases with clear unmet medical needs. The company's two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS). ARDS is a life-threatening form of respiratory failure, and the leading cause of death among COVID-19 patients. Edesa is also developing an sPLA2 inhibitor, designated as EB01, as a topical treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. By targeting sPLA2 with enzyme inhibitors - at the inception of inflammation rather than after inflammation has occurred - Edesa believes that drugs based on this technology could provide a powerful anti-inflammatory therapeutic strategy for treating diverse inflammatory/allergic conditions. The company is based in Markham, Ontario, Canada, with a U.S. subsidiary located in Southern California. Sign up for news alerts. Connect with us on Twitter and LinkedIn.
Edesa Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'plan,' 'estimate,' 'expect,' 'intend,' 'may,' 'will,' 'would,' 'could,' 'should,' 'might,' 'potential,' or 'continue' and variations or similar expressions, including statements related to scheduled events and the company's timing and plans regarding its drug development studies in general. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa's operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa's product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa's ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises, such as COVID-19. Many of these factors that will determine actual results are beyond the company's ability to control or predict. For a discussion of further risks and uncertainties related to Edesa's business, please refer to Edesa's public company reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.
Contacts
Gary Koppenjan
Edesa Biotech, Inc.
(805) 488-2800 ext. 150
[email protected]
SOURCE: Edesa Biotech, Inc.
Get a daily dose of Canada Standard news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Canada Standard.
More InformationCAPE CANAVERAL, Florida: In a landmark flight for three nations and a veteran U.S. spacefarer, a four-member astronaut crew launched...
WASHINGTON, D.C.: In a striking escalation of tensions between the executive and judicial branches, the Trump administration has filed...
BANGKOK, Thailand: This week, Thailand implemented land border restrictions, including a ban on tourists traveling to Cambodia, as...
THE HAGUE, Netherlands: NATO is pressing ahead with a sweeping new defense spending target, calling on all 32 member nations to commit...
NEW YORK, U.S.: A political newcomer is on the verge of reshaping New York City politics. Zohran Mamdani, a 33-year-old state assemblyman...
MADISON, Wisconsin: Tens of millions of residents across the Midwest and East Coast faced dangerously high temperatures over the weekend...
Hyderabad (Telangana) [India], June 28 (ANI): Two-time World Champion Nikhat Zareen opened her campaign with a clinical 4:1 win over...
PHILADELPHIA, June 28 (Xinhua) -- The expanded 2025 FIFA Club World Cup group stage concluded with record-breaking attendance and unprecedented...
Mumbai (Maharashtra) [India], June 28 (ANI): In a celebration of inclusion and the unifying power of sport, Special Olympics Bharat...
Iowa [US], June 28 (ANI): Indian shuttlers Ayush Shetty and Tanvi Sharma advanced into the semi-finals of the ongoing US Open 2025...
New Delhi [India], June 28 (ANI): India's world champion and Olympic gold medalist javelin thrower Neeraj Chopra feels that Indian...
(250628) -- INNSBRUCK, June 28, 2025 (Xinhua) -- Luo Zhilu of China competes during the women's lead qualification at the International...